Heart Aging When Near Vision Difficulty Begins

April 23, 2020 updated by: Şahbender Koç, Kecioren Education and Training Hospital

Near vision deterioration during aging results from a decrease in accomodation amplitude (AA). Myocardial regeneration is limited, and cardiac aging is an independent risk factor for cardiovascular disease. Thus, the investigators investigated the association between cardiac aging and AA.

The subjects (500, mean 50-year-old subjects, with equal males and females) were divided into two groups according to AA measured with a Raf ruler. Biomicroscopy was used to capture images of the lens nucleus in the unaccommodated state, followed by images of a 4 diopter (D) accommodated state. The nucleus diameter change at 1 D accomodation was measured using ImageJ. Cardiac conduction system differences were evaluated using electrocardiography, and cardiac autonomic aging was assessed based on heart rate variability. Myocardial aging was assessed based on diastolic dysfunction.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Lens cells and proteins are encapsulated, and they are not turned over or replaced.The lens nucleus starts to form before birth, so the nucleus is one of the three oldest tissues in the body .With aging, continuous cardiomyocyte stress derails proteostasis by causing excessive autophagy and protease activation, and, ultimately, contractile and electrophysiological dysfunction. Aggregate deposition, proteostasis deterioration, and diffusion degradation between the nucleus and cortex are the main reasons for lens aging.Heart, lens, and neuronal cells change significantly with age, and they are older than cells from renewable tissues.

Near vision deterioration during aging results from a decrease in accomodation amplitude (AA). Cardiac aging is an independent risk factor for cardiovascular disease. Thus, the investigators investigated the association between cardiac aging and AA. The subjects (500 mean 50-year-old subjects, with equal males and females) were divided into two groups according to AA measured with a Raf ruler. The nucleus diameter change at 1 D accomodation was measured using ImageJ. Cardiac conduction system differences, autonomic aging, myocardial aging were evaluated using electrocardiography, heart rate variability and diastolic dysfunction. For near distance vision,compared to subjects who could see clearly from 24-28 cm, subjects who could see clearly from 29-33 cm had a 2.104-fold higher risk of a lateral e' velocity <10 cm/s[95%CI; 1.312-3.374], 2.603-fold higher risk of diastolic dysfunction[95%CI; 1.453-4.662], 1.54-fold higher risk of a low/high frequency ratio >3.1, [95%CI;1.085-2.197]. Subjective AA measurement can predict important heart aging parameters.

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey, 06530
        • ANkara Keçiören EAH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

49 years to 51 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Healthy Volunteers ,mean 50 years of age (49-51)

Description

Inclusion Criteria:

Healthy Volunteers, mean 50 years of age (49-51)

Exclusion Criteria:

Hypertension, Diabetes mellitus, Atrial fibrillation, Coronary artery disease, Arrhythmia, Hyperthyroidism , Anemia, Heart failure, Respiratory diseases, Severe obesity (body mass index ≥35 kg/m2),

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
High AA group
Group 1 consisted of those having an AA level of 3.57-4.16 D (high AA group; those who had near clear vision between 24-28 cm). .
Diagnostic test: Subjective accomodation amplitude measurement
ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
Other Names:
  • ECG,Echocardiography,Holter implementation
Low AA group
Group 2 consisted of those having an AA level of 3.44-3.03 D (low AA group; those who had near clear vision between 29-33 cm)
Diagnostic test: Subjective accomodation amplitude measurement
ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
Other Names:
  • ECG,Echocardiography,Holter implementation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ECG interval changes meauserements(ms,mm,number)
Time Frame: 1 day
ECG PR interval (ms),Ventricle Premature Systol(number),Left Ventricle Hypertrophy(mm)Right Bundle Branch,Left Bundle Branch (the presence / absence)
1 day
Holter implementation
Time Frame: 1 day
To detect autonomic cardiac aging based on heart rate variability (HRV),the low frequency (LF)/high frequency (HF) ratio was measured using a CardioScan II (version 11.4.0054a; DMS Software, Stateline, NV, USA)
1 day
Echocardiographic measurements
Time Frame: 1 day
Diastolic dysfunction meauserements(mitral anulus lateral e' velocity <10 cm/s, average E/e' ratio >14, Left atrium maximum volume index (LAv.i.) >34 mL/m2, and peak Tricuspit Regurgitation velocity >2.8 m/s.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kecioren Education and Training Hospital

Investigators

  • Principal Investigator: Şahbender Koç, University of Health Sciences Ankara Keçiören Education Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 10, 2019

Primary Completion (ACTUAL)

March 15, 2020

Study Completion (ACTUAL)

March 15, 2020

Study Registration Dates

First Submitted

April 20, 2020

First Submitted That Met QC Criteria

April 23, 2020

First Posted (ACTUAL)

April 24, 2020

Study Record Updates

Last Update Posted (ACTUAL)

April 24, 2020

Last Update Submitted That Met QC Criteria

April 23, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 09/2019/1953

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

Clinical Trials on Subjective accomodation amplitude measurement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe